135 related articles for article (PubMed ID: 37351976)
1. Metastasectomy Improves Overall Survival in Metastatic Renal Cell Carcinoma: A Retrospective Cohort Study.
Chiou JK; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY; Hung SC
Anticancer Res; 2023 Jul; 43(7):3193-3201. PubMed ID: 37351976
[TBL] [Abstract][Full Text] [Related]
2. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
Dragomir A; Nazha S; Wood LA; Rendon RA; Finelli A; Hansen A; So AI; Kollmannsberger C; Basappa NS; Pouliot F; Soulières D; Heng DYC; Kapoor A; Tanguay S
Urol Oncol; 2020 Oct; 38(10):799.e1-799.e10. PubMed ID: 32778475
[TBL] [Abstract][Full Text] [Related]
4. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
[TBL] [Abstract][Full Text] [Related]
5. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Hsieh PY; Hung SC; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY
Urol Oncol; 2021 Jul; 39(7):422-430. PubMed ID: 33934963
[TBL] [Abstract][Full Text] [Related]
6. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124
[TBL] [Abstract][Full Text] [Related]
8. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry.
Meagher MF; Mir MC; Autorino R; Minervini A; Kriegmair M; Maurer T; Porpiglia F; Van Bruwaene S; Linares E; Hevia V; Musquera M; Roussel E; Pavan N; Antonelli A; Zhang S; Ghali F; Patel D; Javier-Desloges J; Bradshaw A; Rubio J; Guruli G; Tracey A; Campi R; Albersen M; Furlan M; McKay RR; Derweesh IH
Clin Genitourin Cancer; 2022 Aug; 20(4):326-333. PubMed ID: 35585014
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era.
Takagi T; Fukuda H; Ishihara H; Yoshida K; Kondo T; Kobayashi H; Iizuka J; Okumi M; Ishida H; Omae K; Tanabe K
Urol Oncol; 2020 May; 38(5):515-520. PubMed ID: 32146128
[TBL] [Abstract][Full Text] [Related]
10. Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy.
Holz S; Tosco L; Akand M; Verbiest A; Beuselinck B; Albersen M; Roussel E; Van Poppel H; Joniau S
Urol Oncol; 2020 Dec; 38(12):937.e1-937.e9. PubMed ID: 32900628
[TBL] [Abstract][Full Text] [Related]
11. Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Shimizu T; Miyake M; Nishimura N; Yoshida T; Itami Y; Tachibana A; Omori C; Oda Y; Kohashi M; Tomizawa M; Onishi K; Hori S; Morizawa Y; Dotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398232
[TBL] [Abstract][Full Text] [Related]
12. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.
Yu X; Wang B; Li X; Lin G; Zhang C; Yang Y; Fang D; Song Y; He Z; Zhou L
Biomed Res Int; 2015; 2015():176373. PubMed ID: 26568955
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma.
Li JR; Ou YC; Yang CK; Wang SS; Chen CS; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chiu KY
Anticancer Res; 2018 Sep; 38(9):5339-5345. PubMed ID: 30194186
[TBL] [Abstract][Full Text] [Related]
14. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Zaid HB; Parker WP; Safdar NS; Gershman B; Erwin PJ; Murad MH; Boorjian SA; Costello BA; Thompson RH; Leibovich BC
J Urol; 2017 Jan; 197(1):44-49. PubMed ID: 27473875
[TBL] [Abstract][Full Text] [Related]
15. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.
Zhang H; Chen J; Zhang X; Zhu X; Wang Z; Sun G; Liang J; Chen Y; Shen Y; Liu J; Li X; Wei Q; Liu Z; Zeng H; Shen P
Immunotherapy; 2022 Apr; 14(5):309-320. PubMed ID: 35187953
[No Abstract] [Full Text] [Related]
17. Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival.
Rausch S; Kruck S; Walter K; Stenzl A; Bedke J
Int J Urol; 2016 Nov; 23(11):916-921. PubMed ID: 27520319
[TBL] [Abstract][Full Text] [Related]
18. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
19. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome.
Shin TJ; Song C; Jeong CW; Kwak C; Seo S; Kang M; Chung J; Hong SH; Hwang EC; Park JY; Lee H
J Surg Oncol; 2021 Jan; 123(1):204-213. PubMed ID: 33047324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
